Mediwound (NASDAQ:MDWD) had its price target cut by equities researchers at Oppenheimer from $15.00 to $7.00 in a research note issued to investors on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price indicates a potential upside of 155.47% from the company’s current price.
Several other equities research analysts have also issued reports on MDWD. ValuEngine raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Finally, HC Wainwright assumed coverage on shares of Mediwound in a research note on Monday, August 5th. They issued a “buy” rating and a $5.50 price objective for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $7.25.
MDWD stock opened at $2.74 on Wednesday. The company has a current ratio of 3.99, a quick ratio of 3.79 and a debt-to-equity ratio of 0.40. Mediwound has a 1 year low of $2.55 and a 1 year high of $6.75. The company has a fifty day simple moving average of $3.23 and a 200 day simple moving average of $4.29. The firm has a market cap of $89.01 million, a PE ratio of -5.59 and a beta of 0.49.
Mediwound (NASDAQ:MDWD) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $7.03 million. As a group, analysts forecast that Mediwound will post -0.59 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Delek Group Ltd. acquired a new stake in shares of Mediwound in the 1st quarter valued at $141,000. Meitav Dash Investments Ltd. lifted its position in Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 3,536 shares during the last quarter. Deutsche Bank AG lifted its position in Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares during the last quarter. Menta Capital LLC lifted its position in Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 29,686 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 17,048 shares during the last quarter. 31.16% of the stock is owned by institutional investors and hedge funds.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: Limitations to arbitrage trading
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.